SPLITVAC
Harnessing the innate and adaptive immune system with targeted neoantigen based cancer vaccines
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0SPLITVAC project word cloud
Explore the words cloud of the SPLITVAC project. It provides you a very rough idea of what is the project "SPLITVAC" about.
Project "SPLITVAC" data sheet
The following table provides information about the project.
| Coordinator |
PROTEODESIGN SL
Organization address contact info |
| Coordinator Country | Spain [ES] |
| Total cost | 172˙932 € |
| EC max contribution | 172˙932 € (100%) |
| Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
| Code Call | H2020-MSCA-IF-2018 |
| Funding Scheme | MSCA-IF-EF-SE |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-05-20 to 2021-05-19 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | PROTEODESIGN SL | ES (BARCELONA) | coordinator | 172˙932.00 |
Map
Project objective
Immunotherapy for cancer has recently shown great clinical potential. However, only small percentages of patients do benefit from these therapies. The dual objective of the proposal is to understand and harness the immune system in vivo to develop truly personalized (individualized) anti-cancer treatments and to develop powerful bioconjugation technologies to generate new and better biotherapeutics. The project objectives will be achieved through the combination of ProteoDesign’s site-specific bioconjugation technology, with recent advances in the field of immuno-oncology, particularly the importance of tumor specific mutations (neoantigens), as drivers of anti-tumor immunity. The therapeutic candidates that will be obtained as a result of the project are personalized and have the potential to treat cancer at the individual level. These therapies are based on the mutational landscape of any given tumor, and so they could be applied to multiple cancer indications. The proposal will face specific challenges regarding the development of complex personalized bio therapeutics. The project will be carried out through the collaboration of Dr. Vanhooren and Barcelona based biotech ProteoDesign. Dr. Vanhooren has extensive know-how and experience in the pre-clinical development of biologic-based drugs, and ProteoDesign has a proprietary technology for the discovery and development of new therapeutic bioconjugates. Through the present proposal bidirectional knowledge transfer will take place between the fellow and the host, thus enhancing know-how and skills on both sides. Dr. Vanhooren will be focused on leading the project, setting and adapting objectives, designing experiments, supervising the team and analyzing results. During the project and through a specific plan, ProteoDesign will provide Dr. Vanhooren experience and knowledge in key areas of biotechnology and pharma industries, as well as senior management, to allow her to grow into high responsibility positions.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SPLITVAC" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SPLITVAC" are provided by the European Opendata Portal: CORDIS opendata.